Compass Therapeutics, Inc. (NASDAQ:CMPX) Short Interest Update

Compass Therapeutics, Inc. (NASDAQ:CMPX - Get Free Report) was the recipient of a large increase in short interest in September. As of September 30th, there was short interest totalling 2,490,000 shares, an increase of 8.3% from the September 15th total of 2,300,000 shares. Currently, 2.9% of the company's stock are short sold. Based on an average daily volume of 423,800 shares, the days-to-cover ratio is presently 5.9 days.

Wall Street Analysts Forecast Growth

CMPX has been the subject of a number of analyst reports. HC Wainwright reaffirmed a "buy" rating and set a $10.00 price objective on shares of Compass Therapeutics in a research report on Monday, August 12th. Wedbush restated an "outperform" rating and set a $8.00 price target on shares of Compass Therapeutics in a report on Wednesday, August 7th. Finally, LADENBURG THALM/SH SH upgraded shares of Compass Therapeutics from a "neutral" rating to a "buy" rating and set a $5.00 price target on the stock in a research note on Monday, September 16th.

Hedge Funds Weigh In On Compass Therapeutics

A number of hedge funds have recently bought and sold shares of the business. SG Americas Securities LLC lifted its holdings in shares of Compass Therapeutics by 16.6% during the 3rd quarter. SG Americas Securities LLC now owns 38,665 shares of the company's stock valued at $71,000 after buying an additional 5,515 shares during the period. Rhumbline Advisers increased its position in Compass Therapeutics by 10.3% during the second quarter. Rhumbline Advisers now owns 131,789 shares of the company's stock valued at $132,000 after acquiring an additional 12,315 shares during the last quarter. Bank of New York Mellon Corp lifted its holdings in Compass Therapeutics by 12.4% in the second quarter. Bank of New York Mellon Corp now owns 283,938 shares of the company's stock valued at $284,000 after acquiring an additional 31,433 shares during the period. Bleakley Financial Group LLC purchased a new position in Compass Therapeutics in the first quarter worth about $80,000. Finally, Cubist Systematic Strategies LLC bought a new stake in shares of Compass Therapeutics during the 2nd quarter valued at about $41,000. Hedge funds and other institutional investors own 68.43% of the company's stock.

Compass Therapeutics Price Performance

NASDAQ CMPX traded down $0.07 during mid-day trading on Thursday, reaching $1.91. The stock had a trading volume of 2,218,530 shares, compared to its average volume of 432,007. The stock has a market cap of $262.11 million, a PE ratio of -5.29 and a beta of 0.90. Compass Therapeutics has a 1 year low of $0.77 and a 1 year high of $2.34. The company has a fifty day moving average price of $1.57 and a 200 day moving average price of $1.40.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last posted its earnings results on Monday, August 12th. The company reported ($0.10) EPS for the quarter, hitting analysts' consensus estimates of ($0.10). The business had revenue of $0.85 million during the quarter. As a group, equities research analysts expect that Compass Therapeutics will post -0.42 earnings per share for the current year.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.